Dear [name],

Thank you for your letter of 17 September 2020, on behalf of a joint group of European and international medical and professional specialty societies, regarding endocrine disruptors and the Chemicals Strategy for Sustainability.

On 14 October 2020, the European Commission adopted the Chemicals Strategy for Sustainability. One of its main pillars of action concerns endocrine disruptors including improving the respective legislative framework.

The Joint Research Centre, through a “Fitness Check”, assessed whether relevant EU legislation on endocrine disruptors delivers its overall objective of protecting human health and the environment by minimising exposure to these chemicals. This assessment was used as a basis to develop the actions announced in the Strategy.

One of the central actions is the establishment of a legally binding hazard identification of endocrine disruptors, based on the definition of the WHO, across all legislation. We are already working together with Member States’ experts towards a proposal to include this identification of endocrine disruptors under the Classification, Labelling and Packaging of chemicals (CLP) Regulation and, as a second step, to the global system (UN Globally Harmonised System).

In parallel, we are also working on a proposal to ensure that additional information to be required under the REACH Registration process will allow the identification of substances as endocrine disruptors.

Yours sincerely,

[Signature]

Science Policy
We will also review and strengthen information requirements across legislation (e.g. cosmetic products, food contact materials, plant protection products and biocidal products) to allow the identification of endocrine disruptors in relevant legislations.

Finally, we will ensure that endocrine disruptors are banned in consumer products as soon as they are identified, allowing their use only where it is proven to be essential for society.

I take this opportunity to inform you that the European Commission is organising the Second Annual Forum on Endocrine Disruptors on 17 and 18 December 2020. Due to the current pandemic, the discussions will take place via remote connection. As the Forum is a place to discuss and gather information across stakeholders, we warmly encourage you to participate in this event.

Yours faithfully,

Frans Timmermans

Virginijus Sinkevičius